Sleep-cognition hypothesis In maritime pilots, what is the effect of long-term work-related poor sleep on cognition and amyloid accumulation in healthy middle-aged maritime pilots: Methodology of a case-control study by Thomas, J. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/204875
 
 
 
Please be advised that this information was generated on 2019-12-31 and may be subject to
change.
1Thomas J, et al. BMJ Open 2019;9:e026992. doi:10.1136/bmjopen-2018-026992
Open access 
Sleep-Cognition Hypothesis In 
maritime Pilots, what is the effect of 
long-term work-related poor sleep on 
cognition and amyloid accumulation in 
healthy middle-aged maritime pilots: 
methodology of a case–control study
Jana Thomas,  1,2,3 Sharon Ooms,1,2,3 Marcel Verbeek,2,3,4 Jan Booij,5,6 
Mark Rijpkema,6 Roy P C Kessels,  2,3,7,8 Sebastiaan Overeem,9,10 
Jurgen Claassen1,2,3
To cite: Thomas J, Ooms S, 
Verbeek M, et al.  Sleep-
Cognition Hypothesis In 
maritime Pilots, what is the 
effect of long-term work-
related poor sleep on cognition 
and amyloid accumulation in 
healthy middle-aged maritime 
pilots: methodology of a 
case–control study. BMJ Open 
2019;9:e026992. doi:10.1136/
bmjopen-2018-026992
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
026992). 
Received 1 October 2018
Revised 21 May 2019
Accepted 5 June 2019
For numbered affiliations see 
end of article.
Correspondence to
Miss Jana Thomas;  
 jana. thomas@ radboudumc. nl
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Evidence indicates a bidirectional 
relationship between poor sleep and Alzheimer’s 
disease (AD). While AD may lead to disruption of normal 
sleep, poor sleep in itself may play a causal role in 
the development of AD by influencing the production 
and/or clearance of the amyloid-beta (Aβ) protein. 
This led to the hypothesis that extended periods (>10 
years) of sleep loss could lead to Aβ accumulation 
with subsequent cognitive AD-related decline. This 
manuscript describes the methodology of the SCHIP 
study, a cohort study in maritime pilots that aims 
at investigating the relationship between prolonged 
work-related sleep loss, cognitive function and amyloid 
accumulation among healthy middle-aged maritime 
pilots, to test the hypothesis that prolonged sleep loss 
increases the risk of AD-related cognitive decline.
Methods Our study sample consists of a group of 
healthy middle-aged maritime pilots (n=20), who 
have been exposed to highly irregular work schedules 
for more than 15 years. The maritime pilots will be 
compared to a group of healthy, age and education-
matched controls (n=20) with normal sleep. Participants 
will complete 10 days of actigraphy (Actiwatch 2, Philips 
Respironics) combined with a sleep-wake diary. They 
will undergo one night of polysomnography, followed 
by comprehensive assessment of cognitive function. 
Additionally, participants will undergo amyloid positron 
emission tomography-CT to measure brain amyloid 
accumulation and MRI to investigate atrophy and 
vascular changes.
Analysis All analyses will be performed using IBM SPSS 
V.20.0 (SPSS). We will perform independent samples 
t-tests to compare all outcome parameters.
Ethics and dissemination The study protocol was 
approved by our institutional ethical review board 
(NL55712.091.16, file number 2016–2337) and will be 
performed according to Good Clinical Practice rules. 
Data and results will be published in 2020.
IntroduCtIon
Alzheimer’s disease (AD) is the most preva-
lent cause of dementia and currently affects 
approximately 36 million people worldwide.1 
Thus far, no successful treatment is available. 
One of the major contributors to the neurode-
generation seen in the brains of AD patients 
is amyloid-beta (Aβ).2 The amyloid cascade 
hypothesis characterises amyloid accumula-
tion as the fundamental initiating pathway 
strengths and limitations of this study
 ► The unique cohort of maritime pilots allows the 
prospective assessment of the effect of chronic 
exposure to irregular maritime work schedules on 
cognitive functioning and amyloid accumulation; the 
unique cohort might also be a limitation to the study, 
because they might not be comparable to the con-
trol group to some extent (eg, IQ, work environment, 
personality).
 ► Since we include participants up to 60 years, we will 
have to take possible ageing effects on sleep into 
account while interpreting our results.
 ► In addition to imaging techniques (positron emis-
sion tomography-CT and MRI), we use sensitive and 
well-validated neuropsychological tests to measure 
different domains of cognitive function (reaction 
time, visual memory, executive function, semantic 
memory and episodic memory).
 ► We will make use of four different instruments to ob-
tain a comprehensive measure of sleeping patterns 
(two subjective and two objective ones).
 ► Our results could give rise to new treatment op-
portunities, that aim at sleep improvement and 
management in order to prevent or reduce amyloid 
accumulation and in turn delay or even prevent the 
development of Alzheimer’s disease.
 o
n
 8 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026992 on 27 June 2019. Downloaded from 
2 Thomas J, et al. BMJ Open 2019;9:e026992. doi:10.1136/bmjopen-2018-026992
Open access 
for the development of AD.3 The reason why amyloid 
accumulates, however, is not clear yet. Recent evidence 
suggests that poor sleep might be one of the risk factors 
for amyloid accumulation and thereby increases the 
risk of AD development.4 Elderly people suffering from 
insomnia are more likely to develop AD compared with 
controls without insomnia.4 Furthermore, disrupted 
circadian rhythm among otherwise healthy individuals5 
and sleep-disordered breathing disorders6 increase the 
chance of developing AD later in life. Poor sleep quality 
specifically has been shown to increase the risk of AD 
among older individuals.7–11 A recent meta-analysis of 
epidemiological studies found that poor sleep increased 
AD risk and that approximately 15% of cases of AD in the 
population might be attributable to sleep problems.12 
The effect of acute sleep deprivation on AD has been 
shown in both rodent and human studies, which investi-
gated the effect of sleep and sleep deprivation on Aβ levels. 
Rodents and humans show fluctuations in Aβ levels over a 
24-hour rhythm, where levels rise during wakefulness and 
decrease during sleep.13 14 Following acute sleep depriva-
tion, the drop in Aβ levels that would normally occur after 
sufficient sleep the following morning, was absent. Based 
on this evidence, chronic sleep disturbances might lead 
to a pronounced accumulation of Aβ in the brain, which 
in turn increases the risk to develop AD.
To date, observational and epidemiological studies 
have identified a relationship between poor sleep and 
the risk of developing AD. Experimental research has 
found that sleep deprivation and Aβ levels are related in 
both animals and humans. However, the direct effect of 
chronic partial sleep deprivation and its consequences on 
cognitive functioning, particularly the risk to develop AD 
later in life, has not been studied before.
In this article, we describe the methodology and the 
participant cohort of the Sleep-Cognition Hypothesis In 
maritime Pilots (SCHIP) study. We designed the SCHIP 
study in order to investigate the effect of long-term 
work-related sleep loss on cognitive function, structural 
brain changes and amyloid accumulation by using a 
unique cohort of healthy subjects with highly irregular 
shift work as maritime pilots. Because of the bidirectional 
nature of the relationship between sleep and AD, in which 
poor sleep is a symptom of the disease that precedes the 
clinical manifestation of AD, but might also be a risk factor 
that potentially contributes to the development of the 
disease, it is especially important to investigate the effects 
of sleep loss, caused by an external factor (work) and 
not by an intrinsic sleeping disorder (such as insomnia) 
that could be AD related. Therefore, participants in this 
study were selected based on their prolonged exposure 
to irregular maritime work schedules. In this maritime 
pilot group, sleep loss is characterised as a combination 
of sleep deprivation, sleep restriction and sleep frag-
mentation or disruption. We will refer to these using the 
umbrella term ‘sleep loss’ throughout. An example of an 
individual working schedule from maritime pilot is shown 
in figure 1.
Results and insights born from the SCHIP study could 
shed more light on sleep disturbance as one of the 
risk factors to develop AD and contribute to new and 
improved treatment strategies. In the SCHIP study, we 
will investigate whether maritime pilots perform worse on 
cognitive assessment in comparison to a healthy control 
group and whether they have evidence of elevated brain 
amyloid concentrations and structural brain changes.
MEthods And AnAlysIs
Participants
Considering that this study is a proof-of-principle study, 
it is not possible to establish the exact effect size of the 
change in cognitive function we expect to see between 
the maritime pilots and the healthy controls.
To account for possible 10% withdrawal, we chose to 
have n=20 participants in each arm.
In order to reach enough power to detect clinically 
relevant differences regarding the results of the positron 
emission tomography-CT (PET-CT) scan, we performed a 
sample size power calculation using G Power (V.3.1.9.3).15 
Reported normal values (mean and SD) for this age group 
in the literature vary between studies but are in the order 
of a mean standard uptake value (SUV) between 0.9 and 
1.1 with SDs in the range of 0.05–0.2. We define a relevant 
difference between maritime pilots and normal values to 
be 0.2 or more (an SUV of 1.3 or higher is considered as 
abnormal in most studies). This results in a large expected 
effect size (>0.8). The precise number of age-matched and 
education-matched subjects in the database is not known 
yet but is estimated to be at least 50 (between 50 and 100). 
We have applied a one-tailed test (it is not possible to have 
an SUV lower than normal values). With an alpha of 0.05 
and n=20, our power is 0.95 or higher (depending on the 
number of normal subjects). The lower level for power 
(0.85) is reached with 13–15 pilots.
Based on these calculations, we will aim to recruit 20 
pilots, allowing for drop-out of 5–7 pilots (either due to 
withdrawal of consent or artefacts in the PET-CT).
Participants will be recruited within the national organ-
isation of Dutch Maritime Pilots (Nederlands Lood-
swezen). We selected the maritime pilots as a suitable study 
Figure 1 Example maritime pilot working schedule. Working 
hours indicated in red.
 o
n
 8 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026992 on 27 June 2019. Downloaded from 
3Thomas J, et al. BMJ Open 2019;9:e026992. doi:10.1136/bmjopen-2018-026992
Open access
population because of their unique irregular working 
schedule. They are called to work depending on the 
number and kind of ships that arrive. In a typical 7-day 
work week, they have to be available 24 hours per day 
during which they can be called several times. This results 
in multiple divided short sleep periods over 24 hours 
during a work week, this is followed by a week off. An 
example of a workday of a maritime pilot is illustrated in 
figure 1.
The responsibility of a maritime pilot is to handle large 
international ships arriving by sea and to manoeuvre 
them into their final docking position in one of the Dutch 
harbours. This profession carries high responsibilities 
and requires accurate knowledge of the dimensions of 
the harbour and the ships besides technical knowledge 
and navigational skills. This results in irregular working 
schedules because guiding the ships is a time-intensive 
procedure, which can take hours to complete. Main-
taining this schedule for more than 15 years will result 
in chronic exposure to sleep loss, either due to partial 
sleep deprivation (missing a full night of sleep due to 
work), sleep restriction (a much shorter night of sleep 
than normal) or sleep fragmentation or disruption (short 
periods of sleep interrupted by calls to work).
We will reach out to the whole maritime pilot commu-
nity, in order to recruit pilots who are approximately 
50–60 years old, with at least 15 years of uninterrupted 
work history as a maritime pilot.
Additional inclusion criteria are not using neuro-
active medications or psychostimulants, consumption 
of <14 alcoholic beverages per week, a body mass index 
of 18–30 kg/m2 and no subjective cognitive complaints 
(Cognitive Failure Questionnaire (CFQ <43)). As control 
group, we will recruit 20 age, sex and education matched 
healthy adults with normal sleep indicated by a score of >5 
on a subjective sleep questionnaire (Pittsburgh Sleep 
Quality Index, PSQI). Inclusion of participants started in 
August 2018 and we expect to complete the analysis of all 
data in August 2020.
Experimental design
The aim of the SCHIP study is to investigate the rela-
tionship between long-term work exposure to irreg-
ular working schedules, cognitive function and amyloid 
accumulation among healthy middle-aged men to test 
the hypothesis that work-related prolonged sleep loss 
increases the risk of AD-related cognitive decline. In order 
to test this hypothesis, maritime pilots will have three visits 
and controls will have two visits (figure 2). During the first 
visit, participants will complete general questionnaires 
about medical history, sleeping habits and cognitive state. 
Approximately 10 days after the first visit has taken place, 
participants are invited to the sleep centre Kempenhaeghe 
(Heeze, The Netherlands) for the second visit. They will 
arrive at the sleep centre at 19:00 hours and complete a 
memory consolidation test (modified ‘Doors Test’) and 
a test for attentional performance (TAP 2.3),16 followed 
by overnight polysomnography (PSG). Participants wake 
up at their normal wake time and complete a neuropsy-
chological assessment after breakfast around 09:00 hours.
Visit 3 (only for the maritime pilots) will be performed 
at the Radboud University Medical Center in Nijmegen 
(The Netherlands), where participants will undergo a 
standard amyloid PET-CT to measure brain amyloid accu-
mulation and a 3T-MRI for coregistration. Participants 
are scheduled in their week off in order to prevent short 
term effects of sleep disruption on amyloid concentra-
tions in the brain.17 They are instructed not to eat or drink 
anything except from water 3 hours prior to the scan.
Patient and public involvement
No patients were involved in this study because this study 
involves healthy participants.
However, the participants’ organisation contacted us 
due to recent evidence from the literature on the relation-
ship between sleep and AD. They expressed their worries 
about their health and their own risk of developing AD 
considering their irregular sleep. They reported feeling 
very tired at the end of a work week and speculated 
that within their group of maritime pilots (including 
already retired pilots), cases of dementia occurred more 
frequently than expected.
Figure 2 Overview experimental design. PET, positron 
emission tomography; PSG, polysomnography; TAP, test for 
attentional performance. 
 o
n
 8 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026992 on 27 June 2019. Downloaded from 
4 Thomas J, et al. BMJ Open 2019;9:e026992. doi:10.1136/bmjopen-2018-026992
Open access 
Participants were also tightly involved in the design, 
realisation and feasibility of the study. For example, they 
were involved in choosing the technique to measure 
amyloid and expressed the preference for a PET-CT scan 
over cerebrospinal fluid measurements of amyloid.
Dissemination of results to participants
Results from the PSG measurements will be reported only 
to participants if we find abnormalities such as apnoea or 
sleeping disorders. This will be done by one of our sleep 
clinicians via telephone. Results from the PET-CT scan 
will be disclosed via telephone by one of our clinicians 
as well. This is according to the protocol that has been 
approved by the local ethical committee. Any incidental 
findings on the PET-CT and/or MRI will be disseminated 
as well.
sleep measurements
In order to obtain a comprehensive measure of sleeping 
patterns, we will use the Pittsburgh Sleep Quality Index 
(PSQI) with questions about average sleeping behaviour, 
including the report of bedtime, get-up time, sleep 
latency, total sleep time, sleep disturbances (pain, 
breathing, etc) and use of sleep medication. The mari-
time pilots will be instructed to fill in the questionnaire 
twice, once with regard to a work week and once with 
regard to a week off. Additionally, all participants are 
asked to maintain a sleep-wake diary on a daily basis. In 
this diary, they have to keep track of their bedtimes, the 
time it took to fall asleep (sleep latency), the number of 
awakenings and their get up times. Furthermore, they will 
receive an accelerometer, the Actiwatch 2 (Philips Respi-
ronics; Eindhoven, The Netherlands), in order to obtain 
more objective measurements of sleeping behaviour. The 
Actiwatch is worn around the wrist and measures total 
sleep time and number of awakenings during sleep auto-
matically based on movement. Participants are instructed 
to fill in the sleep diary and to wear the Actiwatch for 10 
days preceding the second visit.
Cognitive assessment
The neuropsychological assessment has been designed to 
measure the following cognitive domains, using validated 
Dutch versions of widely used neuropsychological tests. 
Episodic memory is assessed using the Wechsler Memory 
Scale-IV (WMS-IV) Logical Memory and the Rey-Auditory 
Verbal Learning Test (RAVLT). Working memory and 
executive function are measured by WAIS-IV Digit Span, 
Trail Making Test (TMT-A, TMT-B) and WAIS-IV digit 
symbol test. Semantic memory and language are assessed 
by letter fluency (D-A-T), semantic fluency (animal/
profession naming) and the Boston Naming Test.18 
Attentional performance is studied using the alertness 
test of the Test of Attentional Performance (TAP 2.3).16 
This test is conducted twice, once in the evening around 
19:00 hours and once in the morning around 09.00 hours. 
In order to test overnight memory consolidation, a novel 
paradigm was developed based on the Doors Test, a 
visual recognition task developed by Baddeley et al19 and 
extended using a validated database of 2000 pictures 
of doors.20 During the encoding trial, we present 120 
pictures of doors that participants are instructed to 
remember. All targets (doors) are presented twice in a 
different, pseudo-randomised order. Targets are shown 
for 5 s each, separated by a fixation cross presented for 1 s 
(figure 3). Approximately 10 min after the encoding trial, 
participants are presented with 30 of the original doors 
and 15 distracters (new pictures of doors, not presented 
before) that are randomly mixed. During this short-term 
recognition test, the task is to indicate whether the door 
had been presented before (oral response with ‘yes’) 
or not (oral response ‘no’). For the long-term delayed 
recall, the same procedure is applied in the morning, 
using the other 90 original pictures, plus 45 new distrac-
ters (figure 3). Calculating the hits and false alarms, 
we compute the sensitivity (A′) for short-term and for 
long-term delayed recall (A′=0.5+((hit-rate – false alarm 
rate)×(1+hit rate–false alarm rate))/(4×hit rate×(1–false 
alarm rate)).
Amyloid PEt-Ct scan with co-registered MrI
Brain amyloid PET-CT scan will be performed to 
measure amyloid load. Participants will be scanned at 
the Radboudumc department of Radiology and Nuclear 
medicine on a PET scanner (Biograph mCT, Siemens, 
Erlangen, Germany). Subjects will receive an intravenous 
bolus of the well-validated PET tracer 18F-flutemetamol, 
Figure 3 Memory consolidation task design. (A) Example 
of encoding trials—120 doors separated by fixation cross. 
(B) Example of short-term recognition trials (after approx. 
10 min)—oral response (pressing space-bar to move to 
next stimulus), 30 targets and 15 distracters. (C) Example of 
long-term recognition trials (after one night)—oral response 
(pressing space-bar to move to next stimulus), 90 targets and 
45 distracters. 
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and static brain images will be acquired from 90 to 
110 min postinjection (frames of 5 min), as recom-
mended (see SPC; http://www. ema. europa. eu/ docs/ en_ 
GB/ document_ library/ EPAR_-_ Product_ Information/ 
human/ 002557/ WC500172950. pdf). The individual 
reconstructed PET images will be coregistered with indi-
vidual structural T1 MRI scans.
The PET scans will be rated visually as positive or 
negative by an experienced nuclear medicine physician 
for the presence of amyloid depositions typical of AD. 
Scores will be expressed as a global SUV, which will be 
compared against population normative values, as earlier 
described.21 For quantitative purposes, grey matter 
volumes of interest will be defined on the individual 
MRIs (eg, frontal brain areas, the precuneus and hippo-
campus) as well as for cerebella grey matter (to assess 
non-specific uptake). The amyloid burden will be quanti-
fied using the standardised uptake value ratio, since it has 
been validated that this analysis method has comparable 
agreement with full kinetic modelling.22 Brain MRI will be 
performed on a 3 Tesla system (Magnetom Trio, Siemens, 
Erlangen, Germany). The structural T1-weighted images 
will be used for coregistration purposes, and to define 
grey matter in the volumes of interest. In addition, these 
scans will be used to perform volumetric measurements 
(eg, of the hippocampus). Also, arterial spin labelling 
(ASL) will be performed to measure global and regional 
cerebral blood flow (CBF), since reduced regional CBF 
is an early marker of AD. Individual anatomic MRI scans 
will be coregistered with the individual PET scans using 
the image processing platform FLS ( fsl. fmrib. ox. ac. uk) to 
calculate SUV ratios. The PET-CT data will be expressed 
in Centiloid units to evaluate our data with historical 
control data as was recently validated by Battle et al.23
Future follow-up visits
Because of the insufficient knowledge about the correla-
tion between amyloid accumulation in the brain and the 
actual development of AD, we decided to follow the mari-
time pilots in a 5-year cycle in order to monitor any cogni-
tive changes. We will contact them three times in total, 
which leaves us with a maximum follow-up period of 15 
years. At each time point, they will be asked to answer 
three questions online:
1. Did you develop cognitive complaints over the last 5 
years? This question will be further elaborated on with 
the CFQ. The CFQ is a validated questionnaire that 
aims at detecting daily disruptions of cognitive func-
tions. Participants are confronted with 25 statements 
and have to indicate how often they experience the sit-
uation that is described in the statements with a score 
between 0 (never) and 4 (very often).
2. Were you diagnosed with mild cognitive impairment 
during the last 5 years? If yes, when and what was the 
precise diagnosis?
3. Were you diagnosed with dementia in the past 5 years? 
If yes, when and what was the precise diagnosis?
If the answer is ‘yes’ to one of these questions, we will 
reach out to the participants for clarification.
statistical analysis
All analyses will be performed using IBM SPSS V.20.0 
(SPSS). Statistical significance is set at p<0.05, with 
Bonferroni correction for multiple comparisons when 
appropriate, combined with reports of effect size and 95% 
CIs. All continuous variables will be assessed for normal 
distribution by inspection of histograms and the Kolm-
ogorov-Smirnov test. Levene’s test will be used to assess 
equality of variances. We will perform an independent 
samples t-test to compare all outcome parameters. The 
primary outcome for cognitive function will be the score 
on each test, respectively, adjusted for age and education. 
Regarding imaging, the primary outcome measure will 
be the visual read of the amyloid PET scans (positive or 
negative PET). Secondary outcome measurements will be 
quantitative PET (SUV ratios), brain volume (MRI) and 
CBF measurements (MRI-ASL).
dIssEMInAtIon
Written informed consent will be obtained from all partic-
ipants. We are planning to publish the data and results of 
the SCHIP study in two or three articles in 2019 and 2020.
dIsCussIon
In this article, we presented the design and method-
ology of the SCHIP study. The main aim of the SCHIP 
study is to investigate the effect of long-term work-related 
sleep loss on cognition and amyloid accumulation. Since 
previous studies assessed sleep deprivation for only one 
or a few days, the SCHIP study extends these studies by 
investigating the effect of long term sleep loss on cogni-
tive function and amyloid accumulation. We expect that 
the maritime pilots have had long-term (>15 years) expo-
sure to work-related sleep loss, because of their work 
schedules and that this exposure has led to reduction in 
slow-wave sleep (SWS). Every slow wave observed on an 
electroencephalography is a pause in synaptic activity.24 
Synaptic activity and Aβ levels appear strongly related, as 
Aβ levels increase due to synaptic activity.25 More synaptic 
activity is observed during wakefulness, especially in the 
default mode network or other highly interconnected 
brain areas.25 During sleep, synaptic activity is reduced, 
which could result in a decrease in Aβ levels in the 
brain.25 Therefore, sleep loss (especially poor SWS) over 
the course of many years could increase Aβ concentra-
tions, which in turn could trigger AD-associated neurode-
generation and loss of cognitive function.
To test this hypothesis, we will perform extensive cogni-
tive testing, using tests that are sensitive to subtle decline 
in episodic memory, which is affected early in AD. Addi-
tionally, amyloid positivity will be measured using amyloid 
PET-CT scans in order to explore the effect of work-re-
lated sleep loss on amyloid concentration in the brain. 
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CBF and cerebrovascular resistance will be investigated, 
as reductions in blood flow and increases in resistance 
occur early in the AD process.26 Finally, global grey matter 
volume and hippocampal volume will be measured.
The unique cohort of maritime pilots will allow 
the prospective assessment of prolonged work-re-
lated sleep loss and its consequences for cognitive 
functioning and amyloid accumulation. The design 
of the SCHIP study presents a number of strengths. 
No other previous investigation has looked into the 
effect of chronic partial sleep deprivation on cogni-
tion in healthy men to this extent. Since sleep disor-
ders might also be early symptoms of preclinical AD, it 
is especially important in this age group to investigate 
the effect of sleep loss due to an external factor and 
not due to intrinsic sleep disorders. All enrolled mari-
time pilots did not have any sleeping disorders and did 
not use sleep medication as confirmed by a general 
health questionnaire that was filled in on screening 
for participation. Furthermore, we measure different 
domains of cognitive function (reaction time, visual 
memory, executive function, semantic memory and 
episodic memory) using sensitive and well-validated 
neuropsychological tasks. In addition to testing cogni-
tive functions, we will perform brain imaging to detect 
amyloid accumulation as potential consequence of 
sleep loss. We will make use of four different instru-
ments to get a comprehensive measure of sleeping 
patterns, two subjective and two objective ones. The 
subjective measurements consist of the PSQI and the 
maintenance of the sleep-wake diary. The objective 
assessments include the data from the Actiwatch 2 
(Philips Respironics) in addition to a night of PSG. 
The data from the Actiwatch can be compared with 
the sleep-wake diary entries. These data can then be 
used to verify the sleeping behaviour of participants, 
making sure they maintain regularity and consistency 
in their sleeping habits.
Results of the SCHIP study will give us more insights 
into the consequences of long-term work-related sleep 
loss on cognitive function and amyloid accumula-
tion in an AD-related context. Our results could give 
rise to new treatment opportunities that aim at sleep 
improvement and management in order to prevent 
or reduce amyloid accumulation and in turn delay or 
even prevent the development of AD.
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